Jaka jest cena za Vaxil Bio Ltd. (VXL)

Cena za Vaxil Bio Ltd. (VXL) wynosi $0.1174299

Jaka jest kapitalizacja rynkowa dla Vaxil Bio Ltd. (VXL)

Kapitalizacja rynkowa dla Vaxil Bio Ltd. (VXL) wynosi $467.84K

Vaxil Bio Ltd. (VXL) EPS

Vaxil Bio Ltd. is a biotechnology firm dedicated to discovering and developing innovative therapeutic agents. Its foundation lies in a unique signal peptide-based platform, which it leverages to address critical health challenges, specifically infectious diseases and various cancers. The company's primary therapeutic candidate, ImMucin, has successfully advanced through Phase I/II clinical trials as a potential treatment for multiple myeloma. Beyond ImMucin, Vaxil Bio is actively developing a vaccine/treatment for tuberculosis, as well as a vaccine targeting coronavirus (COVID-19). Strategic alliances bolster its research efforts; Vaxil Bio collaborates with The Tel Aviv Sourasky Medical Center on a research initiative to create a peptide-based COVID-19 vaccine. Furthermore, it holds a Cooperative Research and Development Agreement with the U.S. Army Medical Research Institute of Infectious Diseases to assess CorVax's efficacy in preventing COVID-19 in murine models. Established in 2006, the company's operations are based in Toronto, Canada.

Rok	EPS	Zmień
Za mało danych dla podanych dat.

Rok

EPS

Zmień

Za mało danych dla podanych dat.

Firma	EPS	Różnica w EPS	Kraj
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$13.70	-	BE

Firma

EPS

Różnica w EPS

Kraj

Vertex Pharmaceuticals Incorporated

VRTX.US

$17.32

Argenx SE

ARGX.US

$27.74

Lonza Group AG

LONN.SW

Samsung Biologics Co.,Ltd.

207940.KS

UCB S.A.

UCB.BR

$13.70

Vaxil Bio Ltd.

VXL

Kategoria